These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31127954)

  • 21. Rituximab as a dual therapeutic option for pemphigus and primary cutaneous B-cell lymphomas: Two case reports.
    Michelerio A; Novario M; Barruscotti S; Vassallo C
    Dermatol Ther; 2019 Jul; 32(4):e12948. PubMed ID: 31025498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Haemolytic anaemia following rituximab treatment in a patient with pemphigus vulgaris.
    Li WW; Chen XX; Yu J; Wang Y; Bu DF; Tu P
    Br J Dermatol; 2009 Jul; 161(1):205-6. PubMed ID: 19438448
    [No Abstract]   [Full Text] [Related]  

  • 23. Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?
    Uzuncakmak TK; Özkoca D; Askin O; Kutlubay Z
    Dermatol Ther; 2021 Jan; 34(1):e14647. PubMed ID: 33296557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases.
    Rios-Fernández R; Gutierrez-Salmerón MT; Callejas-Rubio JL; Fernández-Pugnaire M; Ortego-Centeno N
    Br J Dermatol; 2007 Dec; 157(6):1271-3. PubMed ID: 17916218
    [No Abstract]   [Full Text] [Related]  

  • 25. Crescendo response to rituximab in oral pemphigus vulgaris: a case with 7-year follow-up.
    Greenblatt DT; Benton EC; Groves RW; Setterfield JF
    Clin Exp Dermatol; 2016 Jul; 41(5):529-32. PubMed ID: 27061201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus.
    Kikuchi T; Mori T; Shimizu T; Koda Y; Abe R; Kurihara Y; Funakoshi T; Yamagami J; Sato H; Tsunoda K; Amagai M; Okamoto S
    Ann Hematol; 2017 Jul; 96(7):1221-1222. PubMed ID: 28447163
    [No Abstract]   [Full Text] [Related]  

  • 27. Rituximab for the treatment of corticosteroid-refractory pemphigus vulgaris with oral and skin manifestations.
    Craythorne E; du Viver A; Mufti GJ; Warnakulasuriya S
    J Oral Pathol Med; 2011 Sep; 40(8):616-20. PubMed ID: 21385212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
    Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
    Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [[Treatment of therapy resistant pemphigus vulgaris with rituximab and immunoglobulins].
    Mühlhoff C; Megahed M
    Hautarzt; 2007 Nov; 58(11):924-6. PubMed ID: 17952393
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities.
    Cho HH; Jin SP; Chung JH
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):186-91. PubMed ID: 23356542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective case-control study of clinical factors associated with paradoxical exacerbation of pemphigus vulgaris following rituximab infusion.
    Narayanan A; Ramam M; Bhari N
    Int J Dermatol; 2020 Dec; 59(12):e459-e460. PubMed ID: 33197052
    [No Abstract]   [Full Text] [Related]  

  • 32. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up.
    Reguiai Z; Tabary T; Maizières M; Bernard P
    J Am Acad Dermatol; 2012 Oct; 67(4):623-9. PubMed ID: 22261417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intralesional Rituximab in the Treatment of Refractory Oral Pemphigus Vulgaris.
    Vinay K; Kanwar AJ; Mittal A; Dogra S; Minz RW; Hashimoto T
    JAMA Dermatol; 2015 Aug; 151(8):878-82. PubMed ID: 25536513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial.
    Mignard C; Maho-Vaillant M; Golinski ML; Balayé P; Prost-Squarcioni C; Houivet E; Calbo SB; Labeille B; Picard-Dahan C; Konstantinou MP; Chaby G; Richard MA; Bouaziz JD; Duvert-Lehembre S; Delaporte E; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bédane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Joly P; Hébert V;
    JAMA Dermatol; 2020 May; 156(5):545-552. PubMed ID: 32186656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab as Single Long-term Maintenance Therapy in Patients With Difficult-to-Treat Pemphigus.
    Sanchez J; Ingen-Housz-Oro S; Chosidow O; Antonicelli F; Bernard P
    JAMA Dermatol; 2018 Mar; 154(3):363-365. PubMed ID: 29299590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of severe refractory pemphigus vulgaris with rituximab].
    Pitarch G; Sánchez-Carazo JL; Pardo J; Torrijos A; Roche E; Fortea JM
    Actas Dermosifiliogr; 2006; 97(1):48-51. PubMed ID: 16540052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients.
    Brown AE; Motaparthi K; Hsu S
    Dermatol Online J; 2018 Jan; 23(12):. PubMed ID: 29447653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Refractory pemphigus foliaceous treated with rituximab.
    Awdeh F; Gilhooley E; O Grady C; Connolly M
    BMJ Case Rep; 2019 May; 12(5):. PubMed ID: 31147410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained CD19+CD27+ Memory B Cell Depletion after Rituximab Treatment in Patients with Pemphigus Vulgaris.
    Boch K; Langan EA; Schmidt E; Zillikens D; Ludwig RJ; Bieber K; Hammers CM
    Acta Derm Venereol; 2022 Mar; 102():adv00679. PubMed ID: 35312020
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens.
    Wang HH; Liu CW; Li YC; Huang YC
    Acta Derm Venereol; 2015 Nov; 95(8):928-32. PubMed ID: 25881672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.